HK1071890A1 - Spiroazacyclic compounds as monoamine receptor modulators - Google Patents
Spiroazacyclic compounds as monoamine receptor modulatorsInfo
- Publication number
- HK1071890A1 HK1071890A1 HK05104711A HK05104711A HK1071890A1 HK 1071890 A1 HK1071890 A1 HK 1071890A1 HK 05104711 A HK05104711 A HK 05104711A HK 05104711 A HK05104711 A HK 05104711A HK 1071890 A1 HK1071890 A1 HK 1071890A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds
- monoamine receptor
- receptor modulators
- methods
- spiroazacyclic compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Photoreceptors In Electrophotography (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34475001P | 2001-12-28 | 2001-12-28 | |
PCT/US2002/041476 WO2003057698A2 (en) | 2001-12-28 | 2002-12-23 | Spiroazacyclic compounds as monoamine receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1071890A1 true HK1071890A1 (en) | 2005-08-05 |
Family
ID=23351865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05104711A HK1071890A1 (en) | 2001-12-28 | 2005-06-06 | Spiroazacyclic compounds as monoamine receptor modulators |
Country Status (17)
Country | Link |
---|---|
US (6) | US6911452B2 (xx) |
EP (1) | EP1461339B1 (xx) |
JP (1) | JP4535728B2 (xx) |
KR (2) | KR100974901B1 (xx) |
CN (2) | CN100372848C (xx) |
AT (1) | ATE466014T1 (xx) |
AU (1) | AU2009213086A1 (xx) |
BR (1) | BR0215429A (xx) |
CA (1) | CA2470575C (xx) |
DE (1) | DE60236206D1 (xx) |
HK (1) | HK1071890A1 (xx) |
MX (1) | MXPA04006280A (xx) |
NO (1) | NO20042964L (xx) |
NZ (2) | NZ533567A (xx) |
RU (2) | RU2315051C2 (xx) |
WO (1) | WO2003057698A2 (xx) |
ZA (1) | ZA200405028B (xx) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL151164A0 (en) | 2000-03-06 | 2003-04-10 | Acadia Pharm Inc | Azacyclic compounds for use in the treatment of serotonin related diseases |
KR100974901B1 (ko) | 2001-12-28 | 2010-08-10 | 아카디아 파마슈티칼스 인코포레이티드 | 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물 |
US7538222B2 (en) * | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
JP2005533813A (ja) * | 2002-06-24 | 2005-11-10 | アカディア ファーマシューティカルズ,インコーポレーテッド | セロトニン受容体作用物質としてのn−置換ピペリジン誘導体 |
MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
CN101780080B (zh) | 2003-01-16 | 2014-06-04 | 阿卡蒂亚药品公司 | 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂 |
EP2364982A1 (en) * | 2003-04-18 | 2011-09-14 | ONO Pharmaceutical Co., Ltd. | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof |
WO2005023809A1 (en) * | 2003-09-10 | 2005-03-17 | Virochem Pharma Inc. | Spiro compounds and methods for the modulation of chemokine receptor activity |
JPWO2005047286A1 (ja) * | 2003-11-13 | 2007-05-31 | 小野薬品工業株式会社 | スピロ複素環化合物 |
PT1691811E (pt) | 2003-12-11 | 2014-10-30 | Sunovion Pharmaceuticals Inc | Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão |
EP1716156A2 (en) * | 2004-02-10 | 2006-11-02 | F.Hoffmann-La Roche Ag | Chemokine ccr5 receptor modulators |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
EP1604980A1 (en) * | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
EP1790639B1 (en) | 2004-08-27 | 2014-03-26 | Ono Pharmaceutical Co., Ltd. | Spirocyclic compounds and their use as cxcr4-antagonists |
WO2006036874A1 (en) * | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation |
US7790899B2 (en) * | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
WO2006044497A2 (en) | 2004-10-13 | 2006-04-27 | Merck & Co., Inc. | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease |
ES2547724T3 (es) * | 2004-11-10 | 2015-10-08 | Incyte Corporation | Compuestos de lactama y su uso como productos farmacéuticos |
US8110581B2 (en) | 2004-11-10 | 2012-02-07 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
MX2007010728A (es) * | 2005-03-03 | 2007-10-12 | Janssen Pharmaceutica Nv | Derivados sustituidos de oxa-diaza-espiro-[5.5]-undecanona y su uso como antagonistas de la neurocinina. |
US8604200B2 (en) | 2005-03-08 | 2013-12-10 | Janssen Pharmaceutica N.V. | Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists |
US7687243B1 (en) * | 2005-06-06 | 2010-03-30 | Crook Tonia M | Automated method for detecting apoptosis in cells |
DE102005030051A1 (de) * | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
EP1910364B1 (en) | 2005-07-18 | 2012-03-21 | Merck Sharp & Dohme Corp. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
US8168783B2 (en) | 2005-11-18 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
WO2007065256A1 (en) * | 2005-12-06 | 2007-06-14 | Virochem Pharma Inc. | Novel spiropiperidine compounds and methods for the modulation of chemokine receptor activity |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
US8618122B2 (en) | 2006-05-16 | 2013-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having acidic group which may be protected, and use thereof |
WO2008030412A2 (en) * | 2006-09-07 | 2008-03-13 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
MX2009002496A (es) | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US8293759B2 (en) | 2006-10-30 | 2012-10-23 | Merck, Sharp & Dohme, Corp. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
US7659824B2 (en) * | 2006-10-31 | 2010-02-09 | Resurgent Health & Medical, Llc | Sanitizer dispensers with compliance verification |
PL2134330T3 (pl) | 2007-03-19 | 2013-10-31 | Acadia Pharm Inc | Kombinacje odwrotnych agonistów i antagonistów 5-HT2A z antypsychotykami |
CA2682639A1 (en) | 2007-03-29 | 2008-10-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
CL2008001839A1 (es) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
NO2200610T3 (xx) * | 2007-09-21 | 2018-06-09 | ||
AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US8389539B2 (en) * | 2009-12-01 | 2013-03-05 | Hoffman-La Roche Inc. | Azacyclic derivatives |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8097634B2 (en) * | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
RU2603263C2 (ru) * | 2010-07-13 | 2016-11-27 | Ф. Хоффманн-Ля Рош Аг | Новые азациклические соединения |
US20120165331A1 (en) * | 2010-12-22 | 2012-06-28 | Sangamesh Badiger | Di/tri-aza-spiro-C9-C11alkanes |
BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
WO2013052716A1 (en) * | 2011-10-07 | 2013-04-11 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
WO2014008223A2 (en) * | 2012-07-03 | 2014-01-09 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
TW201615643A (zh) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性之1-氧雜-4,9-二氮雜螺十一烷化合物之烷基與芳基衍生物 |
CA2992728A1 (en) | 2015-07-20 | 2017-01-26 | Acadia Pharmaceuticals Inc. | Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c |
MX2018004777A (es) | 2015-10-23 | 2018-06-19 | Esteve Labor Dr | Compuestos oxa-diazaspiro que tienen actividad contra el dolor. |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
US11464768B2 (en) | 2016-12-20 | 2022-10-11 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis |
US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
EP3675827A1 (en) | 2017-08-30 | 2020-07-08 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
CN112169836A (zh) * | 2020-09-28 | 2021-01-05 | 广东石油化工学院 | 一种多孔离子聚合物多相催化剂及其催化合成n-甲酰胺的方法 |
TW202328148A (zh) * | 2021-09-22 | 2023-07-16 | 日商塩野義製藥股份有限公司 | 具有血清素受體結合活性之螺雜環衍生物 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE794333A (fr) | 1972-01-20 | 1973-07-19 | Wyeth John & Brother Ltd | Composes heterocycliques azotes therapeutiques |
GB1507462A (en) | 1974-03-21 | 1978-04-12 | Gallardo Antonio Sa | N-heterocyclic substituted benzamides methods for their preparation and compositions containing them |
US3983234A (en) | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
DE2508188A1 (de) * | 1975-02-26 | 1976-09-09 | Kalk Chemische Fabrik Gmbh | Bis-(guanidinium)-tetrabromdian und verfahren zu dessen herstellung |
GB1586468A (en) | 1976-10-29 | 1981-03-18 | Anphar Sa | Piperidine derivatives |
CA1140119A (en) | 1978-04-03 | 1983-01-25 | Joseph Torremans | N-heterocyclyl-4-piperidinamines |
US4255432A (en) * | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof |
US4332804A (en) | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353901A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353900A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
US4863394A (en) * | 1985-05-20 | 1989-09-05 | General Electric Company | Electrical connector with double torsion contacts |
GB8527052D0 (en) * | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
GB8621892D0 (en) | 1986-09-11 | 1986-10-15 | Lundbeck & Co As H | Organic compound |
FR2642069B1 (fr) | 1989-01-20 | 1991-04-12 | Rhone Poulenc Sante | Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5534520A (en) * | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
US5214055A (en) | 1990-05-18 | 1993-05-25 | Adir Et Compagnie | Aminopiperidine 4-oxo-4H-chromen-2-yl compounds |
US5216165A (en) | 1990-10-03 | 1993-06-01 | American Home Products Corporation | N-substituted aminoquinolines as analgesic agents |
IT1252227B (it) | 1991-12-17 | 1995-06-05 | Ciba Geigy Spa | Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
CA2123728A1 (en) | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
WO1994027967A1 (en) | 1993-05-26 | 1994-12-08 | Smithkline Beecham Laboratoires Pharmaceutiques | Novel compounds |
IL110298A (en) * | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
DE4404183A1 (de) | 1994-02-10 | 1995-08-17 | Merck Patent Gmbh | 4-Amino-1-piperidylbenzoylguanidine |
US5795894A (en) | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
BR9610277A (pt) | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
AU713235B2 (en) | 1995-09-29 | 1999-11-25 | Cor Therapeutics, Inc. | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
US5891889A (en) * | 1996-04-03 | 1999-04-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU715202B2 (en) | 1996-04-03 | 2000-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0960104B1 (en) | 1996-04-17 | 2004-06-16 | Bristol-Myers Squibb Pharma Company | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors |
US5869488A (en) | 1996-05-01 | 1999-02-09 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US5877173A (en) | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
EA004037B1 (ru) | 1996-09-10 | 2003-12-25 | Др. Карл Томэ ГмбХ | Модифицированные аминокислоты и лекарственное средство на их основе |
DE19643331A1 (de) | 1996-10-21 | 1998-04-23 | Thomae Gmbh Dr K | 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
WO1998050534A1 (en) | 1997-05-08 | 1998-11-12 | Smithkline Beecham Corporation | Protease inhibitors |
MXPA00010060A (es) * | 1998-04-14 | 2004-04-23 | Arena Pharm Inc | Receptores de serotonina humana constitutivamente activados, no endogenos y moduladores de molecula pequenos de los mismos. |
US6140509A (en) * | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
US6358698B1 (en) * | 1998-10-07 | 2002-03-19 | Acadia Pharmacueticals Inc. | Methods of identifying inverse agonists of the serotonin 2A receptor |
CA2315050C (en) | 1998-10-16 | 2009-02-03 | Suntory Limited | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof |
US6150393A (en) * | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
EP1013276A1 (en) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
WO2000056335A1 (en) | 1999-03-24 | 2000-09-28 | The Regents Of The University Of California | Methods for treating neurodegenerative disorders using aspartyl protease inhibitors |
US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
IL146006A0 (en) | 1999-05-17 | 2002-07-25 | Novo Nordisk As | Glucagon antagonists/inverse agonists |
US20050148018A1 (en) | 1999-10-07 | 2005-07-07 | David Weiner | Methods of identifying inverse agonists of the serotonin 2A receptor |
FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
IL151164A0 (en) | 2000-03-06 | 2003-04-10 | Acadia Pharm Inc | Azacyclic compounds for use in the treatment of serotonin related diseases |
GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
KR100823908B1 (ko) * | 2000-10-20 | 2008-04-21 | 바이오비트럼 에이비(피유비엘) | 2-, 3-, 4-, 또는 5-치환-n1-(벤젠술포닐)인돌 및 이의치료 용도 |
GB0108099D0 (en) | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
SK14352003A3 (sk) * | 2001-04-25 | 2004-04-06 | Altana Pharma Ag | Piperazino-deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
DE10150897A1 (de) * | 2001-10-18 | 2003-05-15 | Siemens Ag | Schlauchklemmeinrichtung |
KR100974901B1 (ko) | 2001-12-28 | 2010-08-10 | 아카디아 파마슈티칼스 인코포레이티드 | 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물 |
WO2003062206A2 (en) | 2002-01-23 | 2003-07-31 | Arena Pharmaceuticals, Inc. | Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
UY27668A1 (es) | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
GB0208279D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
JP2005533813A (ja) | 2002-06-24 | 2005-11-10 | アカディア ファーマシューティカルズ,インコーポレーテッド | セロトニン受容体作用物質としてのn−置換ピペリジン誘導体 |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
AU2003249983A1 (en) | 2002-07-18 | 2004-02-09 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
WO2004039322A2 (en) | 2002-10-29 | 2004-05-13 | Miicro, Inc. | Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake |
CN101780080B (zh) | 2003-01-16 | 2014-06-04 | 阿卡蒂亚药品公司 | 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂 |
WO2004064753A2 (en) | 2003-01-23 | 2004-08-05 | Acadia Pharmaceuticals Inc | Use of n-desmethylclozapine to treat human neuropsychiatric disease |
ES2271844T3 (es) | 2003-02-17 | 2007-04-16 | F. Hoffmann-La Roche Ag | Derivados de piperidina-bencenosulfonamida. |
WO2005002522A2 (en) * | 2003-06-30 | 2005-01-13 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Compositions and methods for treating tissue ischemia |
MXPA06007244A (es) | 2003-12-22 | 2006-08-18 | Acadia Pharm Inc | Analogos amino sustituidos de diaril[a,d]ciclohepteno como agonistas muscarinicos y metodos de tratamiento de trastornos neuropsiquiatricos. |
US20060288610A1 (en) * | 2004-05-14 | 2006-12-28 | Columbia Sportswear North America, Inc. | Convertible sandal |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
WO2006036874A1 (en) | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation |
KR100707198B1 (ko) * | 2005-06-27 | 2007-04-13 | 삼성전자주식회사 | 나노포어 및 핵산에 비특이적으로 결합하는 물질을 이용한고감도 핵산 검출 방법 |
-
2002
- 2002-12-23 KR KR1020047010194A patent/KR100974901B1/ko not_active IP Right Cessation
- 2002-12-23 US US10/329,719 patent/US6911452B2/en not_active Expired - Lifetime
- 2002-12-23 JP JP2003558013A patent/JP4535728B2/ja not_active Expired - Fee Related
- 2002-12-23 CN CNB028270509A patent/CN100372848C/zh not_active Expired - Fee Related
- 2002-12-23 EP EP02797503A patent/EP1461339B1/en not_active Expired - Lifetime
- 2002-12-23 NZ NZ533567A patent/NZ533567A/en not_active IP Right Cessation
- 2002-12-23 WO PCT/US2002/041476 patent/WO2003057698A2/en active Application Filing
- 2002-12-23 AT AT02797503T patent/ATE466014T1/de not_active IP Right Cessation
- 2002-12-23 RU RU2004123210/04A patent/RU2315051C2/ru not_active IP Right Cessation
- 2002-12-23 CN CNA2007100794326A patent/CN101050215A/zh active Pending
- 2002-12-23 NZ NZ571695A patent/NZ571695A/en not_active IP Right Cessation
- 2002-12-23 BR BR0215429-3A patent/BR0215429A/pt not_active IP Right Cessation
- 2002-12-23 KR KR1020097027553A patent/KR20100008799A/ko not_active Application Discontinuation
- 2002-12-23 CA CA2470575A patent/CA2470575C/en not_active Expired - Fee Related
- 2002-12-23 MX MXPA04006280A patent/MXPA04006280A/es active IP Right Grant
- 2002-12-23 DE DE60236206T patent/DE60236206D1/de not_active Expired - Lifetime
-
2004
- 2004-06-24 ZA ZA2004/05028A patent/ZA200405028B/en unknown
- 2004-07-14 NO NO20042964A patent/NO20042964L/no not_active Application Discontinuation
-
2005
- 2005-06-06 HK HK05104711A patent/HK1071890A1/xx not_active IP Right Cessation
- 2005-06-16 US US11/154,083 patent/US7217719B2/en not_active Expired - Fee Related
-
2006
- 2006-05-03 US US11/417,439 patent/US7402590B2/en not_active Expired - Fee Related
- 2006-05-03 US US11/418,322 patent/US7351707B2/en not_active Expired - Fee Related
-
2007
- 2007-03-16 US US11/687,552 patent/US7511053B2/en not_active Expired - Fee Related
- 2007-07-23 RU RU2007128351/04A patent/RU2007128351A/ru not_active Application Discontinuation
-
2009
- 2009-01-27 US US12/360,478 patent/US7727999B2/en not_active Expired - Fee Related
- 2009-09-11 AU AU2009213086A patent/AU2009213086A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1071890A1 (en) | Spiroazacyclic compounds as monoamine receptor modulators | |
HK1074573A1 (en) | Tetrahydroquinoline analogues as muscarinic agonists | |
TW200634006A (en) | Tetrahydroquinoline analogues as muscarinic agonists | |
YU38801A (sh) | Azabicikloalkani kao modulatori ccr5 | |
IL142768A0 (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
GEP20074197B (en) | 5ht2c receptor modulators | |
DE60112609D1 (en) | Pyrazolopyridine | |
MXPA02012712A (es) | N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas. | |
MY129189A (en) | Prostaglandin agonists and their use to treat bone disorders | |
HUP0301920A2 (hu) | P anyag receptor antagonista és magnézium vegyület kombinációját tartalmazó agy-, gerinc- és idegsérülés kezelésére szolgáló injekciós készítmény | |
AU5624699A (en) | Use of 5ht-6 antagonists | |
HK1077193A1 (en) | Alpha-7 nicotinic receptor agonists and statins incombination | |
BG100830A (en) | Naphthylamides as central nervous system agents | |
UA66865C2 (uk) | Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти) | |
PT1730144E (pt) | Compostos de 1,4,8-triaza-espiro[4.5]decan-2-ona substituídos | |
WO2004084943A8 (en) | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation | |
TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
BR0311898A (pt) | Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3 | |
MXPA01008993A (es) | Tratamiento de combinacion para depresion y ansiedad. | |
EP1254260A4 (en) | METHODS FOR DIAGNOSING AND TREATING A HEART DISEASE | |
PL350568A1 (en) | N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors | |
EP1000071A4 (en) | NEUROLOGICALLY ACTIVE CONNECTIONS | |
MXPA02000680A (es) | Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf. | |
IL144199A0 (en) | Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions | |
WO2004047757A3 (en) | Diagnosing and treating hematopoietic cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20141223 |